Technical Analysis for BIEI - Premier Biomedical

Grade Last Price % Change Price Change
grade F 0.0082 -18.81% -0.0019
BIEI closed down 18.81 percent on Monday, September 16, 2019, on 3.21 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical BIEI trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
20 DMA Support Bullish 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Calm After Storm Range Contraction -18.81%
Inside Day Range Contraction -18.81%
Wide Bands Range Expansion -18.81%
Upper Bollinger Band Touch Strength -18.81%
Crossed Above 20 DMA Bullish -36.92%

Older signals for BIEI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer's disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer's disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.
Medicine RTT Medical Specialties Cancer Pain Diseases Treatment Of Cancer Cancers Dialysis Multiple Sclerosis Alzheimer's Disease Leukemia Fibromyalgia Sepsis Amyotrophic Lateral Sclerosis Traumatic Brain Injury Ms Als Blood Sepsis
Is BIEI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 0.209
52 Week Low 0.005
Average Volume 1,850,788
200-Day Moving Average 0.0357
50-Day Moving Average 0.0097
20-Day Moving Average 0.0077
10-Day Moving Average 0.008
Average True Range 0.0034
ADX 28.84
+DI 35.9244
-DI 14.4958
Chandelier Exit (Long, 3 ATRs ) 0.0097
Chandelier Exit (Short, 3 ATRs ) 0.0162
Upper Bollinger Band 0.0107
Lower Bollinger Band 0.0047
Percent B (%b) 0.58
BandWidth 77.922078
MACD Line -0.0003
MACD Signal Line -0.0008
MACD Histogram 0.0005
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0121
Resistance 3 (R3) 0.0123 0.0111 0.0115
Resistance 2 (R2) 0.0111 0.0101 0.0111 0.0112
Resistance 1 (R1) 0.0097 0.0095 0.0091 0.0095 0.0110
Pivot Point 0.0085 0.0085 0.0083 0.0085 0.0085
Support 1 (S1) 0.0071 0.0075 0.0065 0.0069 0.0054
Support 2 (S2) 0.0059 0.0069 0.0059 0.0052
Support 3 (S3) 0.0045 0.0059 0.0050
Support 4 (S4) 0.0043